SMAIO |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.44 EUR | -0.29% |
|
-1.71% | +11.69% |
| 01-23 | S.M.A.I.O S.A. Announces Unaudited Group Sales Results for the Year Ended December 31, 2023 | CI |
| 2023 | S.M.A.I.O S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2023 | 5.38M 5.85M 461M | Sales 2024 * | 5.4M 5.87M 462M | Capitalization | 17.99M 19.55M 1.54B |
|---|---|---|---|---|---|
| Net income 2023 * | -1M -1.09M -85.63M | Net income 2024 * | -2M -2.17M -171M | EV / Sales 2023 | 2.99 x |
| Net cash position 2023 * | 3.3M 3.59M 283M | Net cash position 2024 * | 400K 435K 34.25M | EV / Sales 2024 * | 3.26 x |
| P/E ratio 2023 * |
-12.7
x | P/E ratio 2024 * |
-8.82
x | Employees | 38 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 99.69% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -0.29% | ||
| 1 week | -1.71% | ||
| Current month | +7.17% | ||
| 1 month | +8.52% | ||
| 3 months | +12.42% | ||
| 6 months | +45.76% | ||
| Current year | +11.69% |
1 week
3.42
3.50
1 month
3.083.50
Current year
2.583.60
1 year
1.903.98
3 years
1.905.75
5 years
1.905.75
10 years
1.905.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 28/12/08 | |
Renaut Fritsch
DFI | Director of Finance/CFO | - | 31/05/22 |
Thibaut Bastien
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 29/07/21 | |
| Director/Board Member | 61 | 29/07/21 | |
Nadia Kamal
BRD | Director/Board Member | - | 21/10/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 3.44 | -0.29% | 35 |
| 16/05/24 | 3.45 | -1.43% | 351 |
| 15/05/24 | 3.5 | +2.04% | 33 |
| 14/05/24 | 3.43 | +0.29% | 1 |
| 13/05/24 | 3.42 | 0.00% | 333 |
Real-time Euronext Paris, May 17, 2024 at 03:42 pm
More quotes
S.M.A.I.O is specialized in the design, manufacture and marketing of implantable medical devices for the treatment of spinal pathologies. The company offers the Kheiron Spinal Fixation System, a device that incorporates a large number of implants, intended for the immobilization and stabilization of spinal segments as an adjunct to fusion of the thoracic, lumbar and/or sacral spine. In addition, S.M.A.I.O has developed the Keops and Balance Analyzer 3D surgical planning and patient database management software, and the company also offers training programs.
Net sales break down by source of revenue between sales of products (95.4%) and services (4.6%).
Export accounts for 54.9% of net sales.
Sector
Pharmaceuticals
Calendar
17/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.44
EUR
Average target price
5.8
EUR
Spread / Average Target
+68.60%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.69% | 19.61M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- ALSMA Stock
